| Name | Title | Contact Details |
|---|---|---|
Katie Thompson |
Chief Human Resources and Compliance Officer | Profile |
Joseph Ohens |
Chief Compliance and Risk Officer | Profile |
Highlights Healthcare is a company that provides diagnosis, early intervention, and ABA therapy services to bring meaningful and positive change to learners with Autism Spectrum Disorder.
Minnesota Visiting Nurse Agency is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
RainDance Technologies, Inc. provides microdroplet-based solutions for single molecule and single cell analysis in the life sciences industry. The company’s RainStorm technology generates various discrete droplets that can encapsulate a single molecule, single cell, or reaction. It offers RDT 1000, a solution that amplifies genomic loci and leverages the sensitivity and specificity of polymerase chain reaction methodology; and ThunderStorm System, a fully automated high-throughput targeted sequencing solution that enables researchers to determine all variation contained in any region of the genome. The company also provides research screening panels, including ASDSeq for autism spectrum disorder research; XSeq for human X-chromosome research; and HLASeq for human leukocyte antigen and major histocompatibility complex research. In addition, it offers sequence enrichment consumables kits that comprise reagents and consumables, and custom-order libraries; and RainDrop Digital PCR System that transforms the performance of molecular assays by enabling digital answers across various applications, including tumor allele detection, gene expression, copy number variation, and SNP measurement. Further, the company provides remote and onsite response for various emergency repairs, including labor and travel, replacement parts and consumables, software revisions, and preventative maintenance. Its RainStorm technology serves various biomedical applications, including genomics research, gene expression analysis, compound screening, and biomarker detection. The company was founded in 2004 and is headquartered in Lexington, Massachusetts.
Children’s of Alabama has provided specialized medical care for ill and injured children across the state and throughout the southeastern U.S. since 1911. For the past three years, Children’s has been ranked among the best children’s hospital programs in the nation by US News & World Report. Last year, patients made more than 634,000 outpatient and nearly 14,000 inpatient visits to Children’s from every county in Alabama and from 47 other states. With more than 2 million square feet, it is the third largest pediatric medical facility in the U.S. Children’s offers inpatient and outpatient services across its Russell Campus on Birmingham’s historic Southside with additional outpatient services provided at Children’s South and Children’s on 3rd. Primary care is provided at more than a dozen offices in communities across central and north Alabama. The Benjamin Russell Hospital for Children is the only hospital in Alabama dedicated solely to the care and treatment of children. It is a private, not-for-profit hospital that serves as the primary site of the University of Alabama at Birmingham (UAB) pediatric medicine, surgery, research and residency programs.
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.